BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Stock Has Average Target Price of $20.50 According to Analysts

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) have been given an average recommendation of “Moderate Buy” by the twelve research firms that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and seven have given a buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $20.50.

BCRX has been the subject of several research analyst reports. Weiss Ratings lowered shares of BioCryst Pharmaceuticals from a “hold (c)” rating to a “sell (d-)” rating in a research note on Tuesday, September 22nd. Needham & Company LLC reissued a “buy” rating and issued a $16.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, September 8th. JPMorgan Chase & Co. boosted their price target on shares of BioCryst Pharmaceuticals from $12.00 to $13.00 and gave the company a “neutral” rating in a research note on Wednesday, September 30th. Wedbush decreased their price objective on shares of BioCryst Pharmaceuticals from $21.00 to $20.00 and set an “outperform” rating on the stock in a report on Thursday, August 6th. Finally, Wall Street Zen cut shares of BioCryst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 29th.

BioCryst Pharmaceuticals Stock Down 2.2%

Shares of BioCryst Pharmaceuticals stock opened at $8.36 on Friday. The firm has a market cap of $2.14 billion, a PE ratio of -5.57 and a beta of 0.55. BioCryst Pharmaceuticals has a 52 week low of $6.00 and a 52 week high of $11.22. The business’s fifty day simple moving average is $9.11 and its 200-day simple moving average is $9.18.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.30 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.15 by $0.15. The firm had revenue of $218.25 million during the quarter, compared to the consensus estimate of $183.28 million. BioCryst Pharmaceuticals had a negative return on equity of 86.89% and a negative net margin of 40.90%. The company’s quarterly revenue was up 33.6% on a year-over-year basis. During the same period last year, the company earned $0.15 EPS. As a group, equities analysts expect that BioCryst Pharmaceuticals will post -2.28 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Bank of America Corp DE grew its stake in shares of BioCryst Pharmaceuticals by 231.6% in the first quarter. Bank of America Corp DE now owns 5,091,765 shares of the biotechnology company’s stock worth $48,474,000 after acquiring an additional 3,556,208 shares in the last quarter. Pacer Advisors Inc. purchased a new stake in shares of BioCryst Pharmaceuticals during the first quarter worth $14,880,000. Wedge Capital Management L L P NC purchased a new stake in shares of BioCryst Pharmaceuticals during the second quarter worth $3,808,000. ADAR1 Capital Management LLC purchased a new stake in shares of BioCryst Pharmaceuticals during the second quarter worth $1,330,000. Finally, Perceptive Advisors LLC raised its stake in shares of BioCryst Pharmaceuticals by 135.1% in the first quarter. Perceptive Advisors LLC now owns 7,434,033 shares of the biotechnology company’s stock valued at $70,772,000 after acquiring an additional 4,271,504 shares in the last quarter. 85.88% of the stock is currently owned by institutional investors and hedge funds.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes oral medicines for rare diseases. The company focuses on small-molecule therapies designed to address diseases with significant unmet medical needs, including hereditary angioedema and complement-mediated disorders.

BioCryst’s primary commercial product is Orladeyo (berotralstat), an oral plasma kallikrein inhibitor used to prevent attacks of hereditary angioedema in adults and pediatric patients.